Lisata Therapeutics

Lisata Therapeutics

Biotechnology
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.

$9M

Market Cap • 10/23/2026

1980

(46 years)

Founded

1999

(27 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

1,1

P/S

89,7

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

0,9

EPS

—

Market Cap

Market Cap

9M

EV

-1,5M

EV/Revenue

-14,7

EV/EBITDA

0,1

EV/EBIT

0,1

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-8,6%

Total Yield

-8,6%

Payout

0%

Retained Earnings

-572,1M

Profitability

Gross Margin

100%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

4881%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

0,1%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

-8,8%

CAGR Net Income 5Y

-9,8%

CAGR EPS 5Y

-33,8%

CAGR OCF 5Y

-10,7%

Leverage

N.D./EBITDA

0,6

Debt/Equity

0%

Current Ratio

3,7

Quick Ratio

3,5

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium